SU 5214
CAS No. 186611-04-1
SU 5214 ( SU 5214 )
Catalog No. M18154 CAS No. 186611-04-1
SU 5214 is a modulator of tyrosine kinase signal transduction.
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 50 | In Stock |
|
10MG | 84 | In Stock |
|
25MG | 170 | In Stock |
|
50MG | 267 | In Stock |
|
100MG | 439 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSU 5214
-
NoteResearch use only, not for human use.
-
Brief DescriptionSU 5214 is a modulator of tyrosine kinase signal transduction.
-
DescriptionSU 5214 is a modulator of tyrosine kinase signal transduction.
-
SynonymsSU 5214
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number186611-04-1
-
Formula Weight251.29
-
Molecular FormulaC16H13NO2
-
Purity98%
-
Solubility——
-
SMILESCOc1ccccc1/C=C/1\c2ccccc2NC1=O
-
Chemical Name3-(2-Methoxy-benzylidene)-1,3-dihydro-indol-2-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Silva JC,et al.Genome-wide diversity and gene expression profiling of Babesia microti isolates identify polymorphic genes that mediate host-pathogen interactions. Sci Rep. 2016 Oct 18;6:35284.
molnova catalog
related products
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
-
(-)-5'-Methoxyisolar...
The root barks of Oplopanax horridus.
-
WAY-659694
WAY-659694 shows moderate acute anti-inflammatory activity and analgesic activity in vivo.